The therapeutic potential of an allosteric non-competitive CXCR1/2 antagonist for diabetic nephropathy.
Chiara GrasselliSilvia BombelliVittoria D'EspositoMichele Francesco Di TollaVincenzo L'ImperioFrancesca RocchioMartina Sara MiscionePietro FormisanoFabio PagniRubina NovelliPier Adelchi RuffiniAndrea AraminiMarcello AllegrettiRoberto A PeregoLidia De FilippisPublished in: Diabetes/metabolism research and reviews (2023)
Treatment with Ladarixin during RSC differentiation prevented high glucose-mediated effects on podocytes and modulated either podocyte or epithelial cell-dependent leucocyte secretion of pro-inflammatory cytokines, suggesting CXCR1/2 antagonists as possible pharmacological approaches for the treatment of diabetic nephropathy.